title: Adalimumab therapy--a double-edged sword?
authors.forename: Donal Peter
authors.initials: DP
authors.lastname: O'Leary
authors.forename: Eddie
authors.initials: E
authors.lastname: Myers
authors.forename: Sarah
authors.initials: S
authors.lastname: Moran
authors.forename: Tara-Jane
authors.initials: TJ
authors.lastname: Browne
authors.forename: Sinead
authors.initials: S
authors.lastname: Harney
authors.forename: William O
authors.initials: WO
authors.lastname: Kirwan
mesh_terms: D000068879:Adalimumab; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects* / Q000627:therapeutic use*; D006801:Humans; D007416:Intestinal Perforation / Q000139:chemically induced / Q000150:complications; D007813:Laparotomy; D008875:Middle Aged; D018805:Sepsis / Q000139:chemically induced / Q000150:complications
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068879:Adalimumab